Raymond James & Associates’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-15,575
| Closed | -$1.06M | – | 3814 |
|
|
2019
Q3 | $1.06M | Buy |
15,575
+3,603
| +30% | +$247K | ﹤0.01% | 2174 |
|
|
2019
Q2 | $696K | Sell |
11,972
-4,086
| -25% | -$242K | ﹤0.01% | 2439 |
|
|
2019
Q1 | $1.13M | Buy |
16,058
+1,782
| +12% | +$132K | ﹤0.01% | 2130 |
|
|
2018
Q4 | $920K | Sell |
14,276
-844
| -6% | -$59.2K | ﹤0.01% | 2138 |
|
|
2018
Q3 | $1.06M | Buy |
15,120
+158
| +1% | +$9.24K | ﹤0.01% | 2225 |
|
|
2018
Q2 | $754K | Buy |
14,962
+624
| +4% | +$24.8K | ﹤0.01% | 2392 |
|
|
2018
Q1 | $449K | Buy |
14,338
+461
| +3% | +$15.3K | ﹤0.01% | 2630 |
|
|
2017
Q4 | $475K | Buy |
13,877
+764
| +6% | +$24.4K | ﹤0.01% | 2562 |
|
|
2017
Q3 | $421K | Buy |
13,113
+379
| +3% | +$12K | ﹤0.01% | 2585 |
|
|
2017
Q2 | $414K | Buy |
+12,734
| New | +$403K | ﹤0.01% | 2539 |
|
|
2015
Q4 | – | Sell |
-23,760
| Closed | -$503K | – | 2427 |
|
|
2015
Q3 | $503K | Buy |
23,760
+1,050
| +5% | +$27.1K | ﹤0.01% | 1919 |
|
|
2015
Q2 | $631K | Buy |
22,710
+6,110
| +37% | +$172K | ﹤0.01% | 1974 |
|
|
2015
Q1 | $507K | Buy |
+16,600
| New | +$528K | ﹤0.01% | 2037 |
|
Raymond James & Associates's GHDX Position: Q4 2019 in Review
Raymond James & Associates sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 15,575 shares — an estimated $1.06M sold.
Raymond James & Associates first reported a position in GHDX in Q1 2015 and held it in 13 quarters. The position peaked at $1.13M in Q1 2019. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Raymond James & Associates reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Raymond James & Associates sold 15,575 Genomic Health, Inc. shares in Q4 2019, an estimated $1.06M.
- Raymond James & Associates first reported a position in Genomic Health, Inc. in Q1 2015 and held it in 13 quarters.
- Raymond James & Associates's Genomic Health, Inc. position peaked at $1.13M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Raymond James & Associates's 13F filing for Q4 2019, filed 12 Feb 2020.